Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: From ASSERT to SUSTAIN and beyond

Belinda A. Di Bartolo, Daniel J. Scherer, Stephen J. Nicholls

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Increasing attention has focused on efforts to promote the biological activities of high-density lipoproteins (HDL) in order to reduce cardiovascular risk. Targeting apolipoprotein A-I (apoA-I), the major protein carried on HDL particles, represents an attractive approach to promoting HDL by virtue of its ability to increase endogenous synthesis of functional HDL particles. A number of pharmacological strategies that target apoA-I, including upregulation of its production with the bromodomain and extraterminal (BET) protein inhibitor RVX-208, development of short peptide sequences that mimic its action, and administration as a component of reconstituted HDL particles, have undergone clinical development. The impact of these approaches on cardiovascular biomarkers will be reviewed.

Original languageEnglish
Pages (from-to)1302-1307
Number of pages6
JournalArchives of Medical Science
Issue number6
Publication statusPublished - Dec 2016


  • Apolipoprotein A-I
  • Atherosclerosis
  • Clinical trials
  • Lipids
  • Risk factors

ASJC Scopus subject areas

  • Medicine(all)

Cite this